N. A. Babakova
Research Subjects
N. A. Babakova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alexandr Kuperin
Pirogov Russian National Research Medical University
2 shared publications - Alexey V. Vasilyiev
Pirogov Russian National Research Medical University
2 shared publications - Denis Anatolevich Andreev
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Dinara F. Mesitskaya
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Российская Федерация
2 shared publications - E.S. An
Pirogov Russian National Research Medical University
2 shared publications - Evgeny I. Seliverstov
Institute of Surgery of the Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Early Recurrence of Deep Vein Thrombosis after Endovascular Mechanical Thrombectomy in Proximal Deep Vein Thrombosis
The article presents a case of treatment proximal deep venous thrombosis using different endovascular approaches. The case emphasizes the importance of individualized approach, monitoring and multidisciplinary management of patients undergoing invasive treatment of deep vein thrombosis (DVT). Patient of 42 years old came with complaints of swelling and bursting pain in the left lower limb lasting 7 days. Iliofemoral venous thrombosis of the left lower limb was confirmed. The patient underwent successful aspiration thrombectomy with subsequent balloon angioplasty. The patient developed re-thrombosis with thrombus extension to the inferior vena cava despite the initial satisfactory outcome of intervention. An inferior vena cava filter was inserted and catheter-directed thrombolysis was performed, which allowed to achieve a good technical result. Attempts of inferior vena cava filter removing in the clinic were unsuccessful and it was successfully excised only in 5 months in another hospital. No DVT recurrence were observed during 12 months of follow-up. The severity of post-thrombotic syndrome was 3 points according to the Villalta scale one year after the treatment. Due to timely diagnosis and comprehensive treatment we achieved stable venous recanalization with favorable long-term outcomes. This case suggests that using only mechanical methods of thrombus extraction without catheter-directed thrombolysis is possible only in case of complete removing ofthrombotic masses.
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Early Recurrence of Deep Vein Thrombosis after Endovascular Mechanical Thrombectomy in Proximal Deep Vein Thrombosis
The article presents a case of treatment proximal deep venous thrombosis using different endovascular approaches. The case emphasizes the importance of individualized approach, monitoring and multidisciplinary management of patients undergoing invasive treatment of deep vein thrombosis (DVT). Patient of 42 years old came with complaints of swelling and bursting pain in the left lower limb lasting 7 days. Iliofemoral venous thrombosis of the left lower limb was confirmed. The patient underwent successful aspiration thrombectomy with subsequent balloon angioplasty. The patient developed re-thrombosis with thrombus extension to the inferior vena cava despite the initial satisfactory outcome of intervention. An inferior vena cava filter was inserted and catheter-directed thrombolysis was performed, which allowed to achieve a good technical result. Attempts of inferior vena cava filter removing in the clinic were unsuccessful and it was successfully excised only in 5 months in another hospital. No DVT recurrence were observed during 12 months of follow-up. The severity of post-thrombotic syndrome was 3 points according to the Villalta scale one year after the treatment. Due to timely diagnosis and comprehensive treatment we achieved stable venous recanalization with favorable long-term outcomes. This case suggests that using only mechanical methods of thrombus extraction without catheter-directed thrombolysis is possible only in case of complete removing ofthrombotic masses.
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Mechanical Endovascular Thromboextraction and Catheter-Directed Thrombolysis in Patients with Iliofemoral Deep Vein Thrombosis of the Lower Extremities: a Single-Center Prospective Cohort Study
Objective. To analyze the efficacy of mechanical thromboextraction (MT) and catheter-directed thrombolysis (CDT) for deep vein thrombosis (DVT) regarding post-thrombotic syndrome (PTS) and quality of life in patients with iliofemoral DVT. Material and methods. A single-center prospective cohort study (January 2022 — June 2024) included patients with iliofemoral DVT eligible for endovascular treatment. Some patients underwent MT and/or CDT. After 6 months, we assessed severity of PTS (Villalta scale) and quality of life (SF-36 and CIVIQ-20 questionnaires). Results. Among 1908 hospitalized patients with DVT, 98 ones met the criteria for invasive treatment. The procedure was performed in 21 (21%) patients. After 6 months, PTS was less severe in patients with iliofemoral DVT who underwent MT and/or CDT compared with those who received conservative treatment alone (Villalta score 3 [2; 5] and 7 [5; 9]; p<0.001). In the invasive treatment group, 71% of patients had Villalta score < 4. In the conservative treatment group, only 9.5% of patients had score < 4. According to the SF-36 questionnaire, there were significant differences in physical health (49.7±10.7 (27—70) and 43.0±9.8 (20—61); p=0.043), while mental health was similar (53 [50; 58] and 52 [49; 55]; p=0.351). According to the CIVIQ-20 questionnaire, quality of life was significantly higher in the group of invasive treatment (85 [78; 89] and 70 [64; 78]; p=0.009). Conclusions. MT and/or CDT in iliofemoral DVT reduces the likelihood and severity of post-thrombotic syndrome, as well as contributes to better quality of life throughout 6-month follow-up.
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Mechanical Endovascular Thromboextraction and Catheter-Directed Thrombolysis in Patients with Iliofemoral Deep Vein Thrombosis of the Lower Extremities: a Single-Center Prospective Cohort Study
Objective. To analyze the efficacy of mechanical thromboextraction (MT) and catheter-directed thrombolysis (CDT) for deep vein thrombosis (DVT) regarding post-thrombotic syndrome (PTS) and quality of life in patients with iliofemoral DVT. Material and methods. A single-center prospective cohort study (January 2022 — June 2024) included patients with iliofemoral DVT eligible for endovascular treatment. Some patients underwent MT and/or CDT. After 6 months, we assessed severity of PTS (Villalta scale) and quality of life (SF-36 and CIVIQ-20 questionnaires). Results. Among 1908 hospitalized patients with DVT, 98 ones met the criteria for invasive treatment. The procedure was performed in 21 (21%) patients. After 6 months, PTS was less severe in patients with iliofemoral DVT who underwent MT and/or CDT compared with those who received conservative treatment alone (Villalta score 3 [2; 5] and 7 [5; 9]; p<0.001). In the invasive treatment group, 71% of patients had Villalta score < 4. In the conservative treatment group, only 9.5% of patients had score < 4. According to the SF-36 questionnaire, there were significant differences in physical health (49.7±10.7 (27—70) and 43.0±9.8 (20—61); p=0.043), while mental health was similar (53 [50; 58] and 52 [49; 55]; p=0.351). According to the CIVIQ-20 questionnaire, quality of life was significantly higher in the group of invasive treatment (85 [78; 89] and 70 [64; 78]; p=0.009). Conclusions. MT and/or CDT in iliofemoral DVT reduces the likelihood and severity of post-thrombotic syndrome, as well as contributes to better quality of life throughout 6-month follow-up.
- Open Access
- 1 July 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (6) , 52-58
Results of Register in Patients with Acute Coronary Syndrome and Atrial Fibrillation Receiving Rivaroxaban
Aim To evaluate outcomes in patients with acute coronary syndrome and atrial fibrillation who receive rivaroxaban and the patients’ compliance with the antithrombotic therapy. Material and methods The study was performed from October 2017 through December 2019 and included 129 patients. Events between the discharge from the hospital and 12 months of follow-up were recorded. The primary endpoint was development of major, minor or requiring medical attention bleeding according to the TIMI scale. The secondary endpoint was a combination of recurrent myocardial infarction, nonfatal acute ischemic cerebrovascular disease, nonfatal systemic embolism, stent thrombosis, and cardiovascular mortality. Results 32 (24.8%) patients early terminated the antiplatelet treatment and 22 (17.1%) patients terminated the rivaroxaban treatment. 26 (20.2 %) patients had hemorrhagic complications. The highest incidence of hemorrhage was observed within the first 2 months after the discharge. None of the bleedings was fatal. Composite endpoint events were observed in 24 (18.6 %) patients, including 14 (10.9 %) who died from cardiovascular causes. Conclusion The compliance with the antiplatelet therapy was insufficient. The incidence of hemorrhagic complications was relatively high; minor and requiring medical attention hemorrhages mostly contributed to the structure of these complications. The observed incidence of recurrent ischemic events associated with a high mortality presents a more serious problem compared to hemorrhagic complications of the combination antiplatelet therapy and warrants a more aggressive tactics of the antiplatelet treatment in high-risk patients.
- 1 July 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (6) , 52-58
Open AccessResults of Register in Patients with Acute Coronary Syndrome and Atrial Fibrillation Receiving Rivaroxaban
Aim To evaluate outcomes in patients with acute coronary syndrome and atrial fibrillation who receive rivaroxaban and the patients’ compliance with the antithrombotic therapy. Material and methods The study was performed from October 2017 through December 2019 and included 129 patients. Events between the discharge from the hospital and 12 months of follow-up were recorded. The primary endpoint was development of major, minor or requiring medical attention bleeding according to the TIMI scale. The secondary endpoint was a combination of recurrent myocardial infarction, nonfatal acute ischemic cerebrovascular disease, nonfatal systemic embolism, stent thrombosis, and cardiovascular mortality. Results 32 (24.8%) patients early terminated the antiplatelet treatment and 22 (17.1%) patients terminated the rivaroxaban treatment. 26 (20.2 %) patients had hemorrhagic complications. The highest incidence of hemorrhage was observed within the first 2 months after the discharge. None of the bleedings was fatal. Composite endpoint events were observed in 24 (18.6 %) patients, including 14 (10.9 %) who died from cardiovascular causes. Conclusion The compliance with the antiplatelet therapy was insufficient. The incidence of hemorrhagic complications was relatively high; minor and requiring medical attention hemorrhages mostly contributed to the structure of these complications. The observed incidence of recurrent ischemic events associated with a high mortality presents a more serious problem compared to hemorrhagic complications of the combination antiplatelet therapy and warrants a more aggressive tactics of the antiplatelet treatment in high-risk patients.
- Open Access
- 7 May 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2) , 186-192
Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran
Atrial fibrillation (AF) is the most frequent type of supraventricular arrhythmias. The anticoagulant therapy should be prescribed to prevent thromboembolic events. According to randomized clinical trials, anticoagulants do not always prove their high efficiency in the real clinical practice. It is a complicated issue for any doctor to prescribe the anticoagulant therapy for patients with AF and CKD. 30 % of patients with atrial fibrillation are known to have chronic kidney disease, while 10-15% of patients with chronic kidney disease are diagnosed with atrial fibrillation. Currently, there are scarce studies into the use of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease (in case of Glomerular Filtration Rate (GFR) below 45 ml/min/1.73 m2).Aim. To determine the dynamics of GFR in patients with AF and CKD (in case of GFR below 45 ml/min/1.73 m2).Material and Methods. The sub-analysis was carried out to examine a single-centre prospective study into the optimization of the anticoagulant therapy in the outpatient practice. Initially, 133 dabigatran taking patients were enrolled in the study, and 79 patients were included in the final analysis. Endpoints were changes in Glomerular Filtration Rate (CKD-EPI) formulae as of the inclusion date, in 6, 12, 24 and 60 months after the inclusion. Changes in the renal function shall mean a decrease or increase in GFR by ≥5 ml/min.Results. The average follow-up period for patients was 1785 ± 218 days. A GFR>45 ml/min/1.73 m2 occurred in 116 (87.2%) patients, and a GFR 2 was found in 17 (12.8%) patients. The average HAS-BLED score was 1.8, and CHA2DS2VASc score - 3.8. During the observation period, there were 3 cases of major bleeding and 133 cases of minor bleeding. Both major (р=0.025) and minor (р=0.012) bleeding were statistically significant more frequent in patients with GFR below 45 ml/min. During 5 years of follow-up, 66 (49.6%) patients had an average decrease in GFR of 3.32 ml/min/1.73 m2 per year. Patients with the initially declined GFR (below 45 ml/min) did not demonstrate a significant dynamic of the renal function during the dabigatran therapy. The mortality rate in this group during the observation period was 61.5%.Conclusion. In 49.6% of patients during 5 years of follow-up, GFR decreased by an average of 3.32 ml/min/1.73 m2 per year, which does not exceed the indicators typical for patients with cardiovascular events and CKD.
- 7 May 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2) , 186-192
Open AccessDynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran
Atrial fibrillation (AF) is the most frequent type of supraventricular arrhythmias. The anticoagulant therapy should be prescribed to prevent thromboembolic events. According to randomized clinical trials, anticoagulants do not always prove their high efficiency in the real clinical practice. It is a complicated issue for any doctor to prescribe the anticoagulant therapy for patients with AF and CKD. 30 % of patients with atrial fibrillation are known to have chronic kidney disease, while 10-15% of patients with chronic kidney disease are diagnosed with atrial fibrillation. Currently, there are scarce studies into the use of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease (in case of Glomerular Filtration Rate (GFR) below 45 ml/min/1.73 m2).Aim. To determine the dynamics of GFR in patients with AF and CKD (in case of GFR below 45 ml/min/1.73 m2).Material and Methods. The sub-analysis was carried out to examine a single-centre prospective study into the optimization of the anticoagulant therapy in the outpatient practice. Initially, 133 dabigatran taking patients were enrolled in the study, and 79 patients were included in the final analysis. Endpoints were changes in Glomerular Filtration Rate (CKD-EPI) formulae as of the inclusion date, in 6, 12, 24 and 60 months after the inclusion. Changes in the renal function shall mean a decrease or increase in GFR by ≥5 ml/min.Results. The average follow-up period for patients was 1785 ± 218 days. A GFR>45 ml/min/1.73 m2 occurred in 116 (87.2%) patients, and a GFR 2 was found in 17 (12.8%) patients. The average HAS-BLED score was 1.8, and CHA2DS2VASc score - 3.8. During the observation period, there were 3 cases of major bleeding and 133 cases of minor bleeding. Both major (р=0.025) and minor (р=0.012) bleeding were statistically significant more frequent in patients with GFR below 45 ml/min. During 5 years of follow-up, 66 (49.6%) patients had an average decrease in GFR of 3.32 ml/min/1.73 m2 per year. Patients with the initially declined GFR (below 45 ml/min) did not demonstrate a significant dynamic of the renal function during the dabigatran therapy. The mortality rate in this group during the observation period was 61.5%.Conclusion. In 49.6% of patients during 5 years of follow-up, GFR decreased by an average of 3.32 ml/min/1.73 m2 per year, which does not exceed the indicators typical for patients with cardiovascular events and CKD.